Picture of ADICET Bio logo

ACET — ADICET Bio News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Adicet Bio Inc expected to post a loss of 68 cents a share - Earnings Preview

* Adicet Bio Inc  ACET.OQ   ACET.O  is expected to show a
rise in
quarterly revenue when it reports  results on August 8
(estimated). 
    * The Boston Massachusetts-based  company is expected to
report
revenue of $12.667 million, according to the mean estimate from
9 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Adicet Bio Inc is
for a
loss of 68 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adicet Bio
Inc is
$23.5​, above​ its last closing price of $2.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.71       -0.69      -0.72     Missed  -4.8
 Dec. 31 2023  0.29        -0.28      -0.72     Missed  -158.1
 Sep. 30 2022  -0.55       -0.53      -0.53     Met     -0.6​
 Jun. 30 2022  -0.44       -0.45      -0.56     Missed  -23.1
 ​​Mar.        -0.24       -0.18      0.10      Beat    154.9
 31 2022                                                
 Dec. 31 2021  -0.25       -0.42      -0.47     Missed  -11.6​
 Sep. 30 2021  -0.44       -0.44      -0.44     Met     0
 Jun. 30 2021  -0.53       -0.53      -0.34     Beat    35.8
 This summary was machine generated August 4 at 15:27 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on ADICET Bio

See all news